William Shelton, MD
Family Medicine · Clarinda, IANPI 1952349268
Payments from drug & device makers
Across 158 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$411
- Novo Nordisk$381
- Mylan Specialty L.p.$264
- Amgen$156
- Novartis$127
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$79
- plus $831 from 27 others
What the payments were for
- Food & beverage$2,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $411 |
| Novo Nordisk | 27 | $381 |
| Mylan Specialty L.p. | 18 | $264 |
| Amgen | 11 | $156 |
| Novartis | 9 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $79 |
| Boehringer Ingelheim | 5 | $64 |
| Viatris Specialty LLC | 4 | $61 |
| Merck | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Astellas Pharma US Inc | 4 | $55 |
| Lilly USA, LLC | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Bayer | 3 | $43 |
| Insulet Corporation | 2 | $40 |
| Johnson & Johnson | 3 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Medtronic | 1 | $26 |
| AstraZeneca | 2 | $25 |
| GSK | 1 | $18 |
| Vertex | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Pfizer | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$2,249 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 148 | $115,898 |
| EliquisApixaban | 174 | $113,687 |
| OzempicSemaglutide | 101 | $102,533 |
| MounjaroTirzepatide | 40 | $43,483 |
| XareltoRivaroxaban | 31 | $37,895 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $31,618 |
| FarxigaDapagliflozin Propanediol | 25 | $25,017 |
| TrulicityDulaglutide | 13 | $22,741 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 66 | $20,326 |
| JanuviaSitagliptin Phosphate | 30 | $18,715 |
| EntrestoSacubitril/Valsartan | 13 | $18,084 |
| MyrbetriqMirabegron | 52 | $17,292 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $13,757 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $11,905 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $11,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $64 | $125,247168 claims |
| PfizerEliquis, Premarin | $12 | $118,850190 claims |
| Novo NordiskOzempic | $381 | $102,533101 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Incruse Ellipta | $18 | $70,612131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $66,22453 claims |
| Johnson & JohnsonXarelto | $35 | $37,89531 claims |
| AstraZenecaFarxiga | $25 | $25,01725 claims |
| MerckJanuvia | $58 | $18,71530 claims |
| NovartisEntresto | $127 | $18,08413 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $17,29252 claims |
| AbbVieLinzess | $411 | $10,21415 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $3,483409 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Clarinda
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.